Galectin-3 (Gal-3) has emerged as a central mediator of myocardial inflammation and fibrosis in cirrhotic cardiomyopathy (CCM), underscoring its dual role as both a pathogenic effector and a potential biomarker. The gene discussed is LGALS3; the disease is cerebral cavernous malformation.